Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression

17 Dec 2010

Abstract excerpt

Modulating aberrant transcription of oncogenes is a relatively unexplored opportunity in cancer therapeutics. In approximately 10% of multiple myelomas, the initiating oncogenic event is translocation of musculoaponeurotic fibrosarcoma oncogene homolog (MAF), a transcriptional activator of key target genes, including cyclinD2. Our prior work showed that MAF is up-regulated in an additional 30% of multiple myeloma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Melanoma and MAPK Pathways
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21163924
DOI: 10.1182/blood-2010-04-278788

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expressionPMID 21163924Read ↗

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activationSemantic proximity Read ↗

POZ Domain Transcription Factor Kaiso is a Downstream Effector of STAT1 for Multiple Myeloma Cell Survival and is also essential for Anoikis Resistance of Metastatic Solid TumorsSemantic proximity Read ↗

Identification of primary MAFB target genes in multiple myelomaSemantic proximity Read ↗

Selective Enhancer Gain-of-Function Deregulates MYC Expression in Multiple MyelomaSemantic proximity Read ↗

FHND004 inhibits malignant proliferation of multiple myeloma by targeting PDZ-binding kinase in MAPK pathway.Semantic proximity Read ↗

GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic targetSemantic proximity Read ↗

Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS.Semantic proximity Read ↗

Overexpression of RKIP and its cross-talk with several regulatory gene products in multiple myelomaSemantic proximity Read ↗

Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma.Semantic proximity Read ↗

Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myelomaSemantic proximity Read ↗

Kinase domain activation through gene rearrangement in multiple myeloma.Semantic proximity Read ↗

MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.